We are focused on developing differentiated products for the treatment and prevention of serious infectious diseases. Our clinical-stage programs include INX-189 and FV-100 which are potent, orally available, antiviral for the treatment of herpes zoster (shingles), and Aurexis^®, a humanized monoclonal antibody for the adjunct treatment of serious S. aureus infections. Antiviral programs in pre-clinical development include differentiated oral compounds for the treatment of HCV. We have licensed our MSCRAMM^® protein platform technology to Pfizer for use in the development of vaccines to prevent S. aureus infection.